Lazard Asset Management’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $21K | Sell |
155
-249
| -62% | -$33.7K | ﹤0.01% | 2119 |
|
|
2025
Q1 | $72K | Sell |
404
-72
| -15% | -$12.8K | ﹤0.01% | 1906 |
|
|
2024
Q4 | $74K | Sell |
476
-922
| -66% | -$143K | ﹤0.01% | 1890 |
|
|
2024
Q3 | $253K | Sell |
1,398
-26
| -2% | -$4.71K | ﹤0.01% | 1552 |
|
|
2024
Q2 | $259K | Buy |
1,424
+116
| +9% | +$21.1K | ﹤0.01% | 1474 |
|
|
2024
Q1 | $232K | Buy |
1,308
+282
| +27% | +$50K | ﹤0.01% | 1252 |
|
|
2023
Q4 | $125K | Buy |
1,026
+19
| +2% | +$2.32K | ﹤0.01% | 1570 |
|
|
2023
Q3 | $115K | Buy |
1,007
+294
| +41% | +$33.6K | ﹤0.01% | 1583 |
|
|
2023
Q2 | $82K | Buy |
713
+245
| +52% | +$28.2K | ﹤0.01% | 1653 |
|
|
2023
Q1 | $36K | Buy |
468
+100
| +27% | +$7.69K | ﹤0.01% | 1894 |
|
|
2022
Q4 | $28K | Sell |
368
-1,482
| -80% | -$113K | ﹤0.01% | 2055 |
|
|
2022
Q3 | $128K | Buy |
1,850
+6
| +0.3% | +$415 | ﹤0.01% | 1373 |
|
|
2022
Q2 | $120K | Buy |
1,844
+73
| +4% | +$4.75K | ﹤0.01% | 1450 |
|
|
2022
Q1 | $117K | Buy |
1,771
+499
| +39% | +$33K | ﹤0.01% | 1356 |
|
|
2021
Q4 | $88K | Buy |
1,272
+221
| +21% | +$15.3K | ﹤0.01% | 1489 |
|
|
2021
Q3 | $54K | Sell |
1,051
-522
| -33% | -$26.8K | ﹤0.01% | 1652 |
|
|
2021
Q2 | $106K | Buy |
1,573
+1,541
| +4,816% | +$104K | ﹤0.01% | 1325 |
|
|
2021
Q1 | $2K | Hold |
32
| – | – | ﹤0.01% | 1808 |
|
|
2020
Q4 | $1K | Buy |
+32
| New | +$1K | ﹤0.01% | 1819 |
|